Description
HS-10502 is an experimental drug currently being studied in clinical trials for advanced solid tumors, including colorectal cancer. It is being investigated to see if it is safe, how the body processes it (pharmacokinetics), and if it has any effect on the cancer (efficacy). This drug is specifically designed to target PARP1, an enzyme involved in DNA repair within cancer cells. The trial is looking at patients whose tumors have specific genetic changes (mutations in HRR genes or HRD positivity) that might make them more sensitive to this type of drug. HS-10502 is being tested in Phase 1 trials, which primarily focus on safety and determining the right dosage.
Mechanism of Action
HS-10502 is described as a PARP1-specific selective inhibitor. PARP1 is an enzyme that helps repair damaged DNA in cells. By inhibiting PARP1, HS-10502 aims to prevent cancer cells from repairing their DNA, potentially leading to their death, especially in tumors with defects in DNA repair pathways (like those with HRR gene mutations or HRD positivity).
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.